Four cases of COVID-19 associated Guillain-Barré syndrome
10.3760/cma.j.cn113694-20230816-00058
- VernacularTitle:新型冠状病毒感染相关吉兰-巴雷综合征4例
- Author:
Yalin GUAN
1
;
Yunhan FEI
;
Changshen YU
;
Pan WANG
;
Hao WU
;
Xuemei QI
;
Xinping WANG
;
Wenjuan ZHAO
Author Information
1. 天津市环湖医院神经内科，天津 300050
- Keywords:
COVID-19;
Guillain-Barré syndrome;
Azvudine
- From:
Chinese Journal of Neurology
2024;57(1):80-84
- CountryChina
- Language:Chinese
-
Abstract:
COVID-19 associated Guillain-Barré syndrome (GBS) caused by peripheral nerve damage after SARS-CoV-2 infection is one of the most common COVID-19 related nervous system inflammatory diseases, with high incidence of respiratory failure and mortality. Positive SARS-CoV-2 RNA in cerebrospinal fluid of COVID-19 associated GBS patients has been rarely reported. This paper reports 4 patients with COVID-19 associated GBS in China who developed neurological symptoms 4-15 days after fever and were confirmed SARS-CoV-2 infection. All patients presented with progressive weakness of both lower limbs, 3 patients with autonomic dysfunction such as defecation and urination disorders, and 1 patient with polycranial neuritis and Miller-Fisher syndrome such as bilateral facial palsy, dysphagia, diplopia and ataxia. Nerve conduction velocity and F wave were abnormal in 3 patients, and motor conduction pathway was abnormal in 1 patient. Anti-ganglioside antibodies were tested in 3 patients, and GD1a-IgG was positive in 1 patient. All 4 patients underwent metagenomic next-generation sequencing examination in blood and cerebrospinal fluid. SARS-CoV-2 RNA was positive in blood and cerebrospinal fluid of 3 patients, and SARS-CoV-2 RNA was positive in cerebrospinal fluid of 1 patient.
